Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study

References

• Tegeder I, Lotsch J, Krebs S, et al. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Therapeut 1999;65:533-44
   PubMed Web of Science ®Google Scholar
• Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-20
   PubMed Web of Science ®Google Scholar
• Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res 2015;8:105-18
   PubMed Web of Science ®Google Scholar
• Albengres E, Urien S, Barre J, et al. Clinical pharmacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity. Int J Tissue React 1993;15:125-34
   PubMedGoogle Scholar
• Bartholomew M. Top 200 Drugs of 2012. Pharmacy Times, 2013. Available at: http://www.pharmacytimes.com/publications/issue/2013/july2013/top-200-drugs-of-2012 [Last accessed 25 September 2015]
   Google Scholar
• Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002;32(3 Suppl 1):33-42
   PubMed Web of Science ®Google Scholar
• Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769–79
   PubMed Web of Science ®Google Scholar
• Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case–control study. Lancet 2005;365:475-81
   PubMed Web of Science ®Google Scholar
• Lewis SC, Langman MJ, Laporte JR, et al. Dose–response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002;54:320-6
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8:e1001098
   PubMed Web of Science ®Google Scholar
• Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case–control study. BMJ (Clinical research ed) 2011;343:d3450
   PubMed Web of Science ®Google Scholar
• Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106:13-24s
   PubMedGoogle Scholar
• Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996;35(Suppl 1):68-77
   PubMedGoogle Scholar
• Public Health Advisory – FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). 2005. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm [Last accessed 25 September 2015]
   Google Scholar
• FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm451800.htm 07/17/2015 [Last accessed 14 July 2015]
   Google Scholar
• Olugemo K, Parenti D, Young C. [Abstract AB0869] Pharmacokinetics and safety of lower-dose SoluMatrix meloxicam in healthy adults. Ann Rheum Dis 2014;73(Suppl 2):1089
   Web of Science ®Google Scholar
• Desjardins PJ, Olugemo K, Solorio D, Young CL. Pharmacokinetic properties and tolerability of low-dose SoluMatrix diclofenac. Clin Ther 2015;37:448-61
   PubMed Web of Science ®Google Scholar
• Olugemo K, Solorio D, Sheridan C, Young CL. Pharmacokinetics and safety of low-dose submicron indomethacin 20 and 40 mg compared with indomethacin 50 mg. Postgraduate Med 2015;127:223-31
   PubMed Web of Science ®Google Scholar
• Altman R, Hochberg M, Gibofsky A, et al. Low-dose SoluMatrix meloxicam demonstrates low systemic exposure and efficacy in patients with osteoarthritis pain in clinical studies. Osteoarthritis Cartilage 2015;23(Suppl 2):A324-5
   Web of Science ®Google Scholar
• Full Prescribing Information for VIVLODEX. 2015. Iroko Pharmaceuticals, LLC. Available at: https://www.vivlodex.com/wp-content/uploads/2015/10/vivlodex-prescribing-information.pdf. [Last accessed 4 November 2015]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207233s000lbl.pdf. [Last accessed 17 November 2015]
   Google Scholar
• Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494-502
   PubMed Web of Science ®Google Scholar
• Baber N. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Br J Clin Pharmacol 1994;37:401-4
   PubMed Web of Science ®Google Scholar
• World Medical Association. Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-6
   PubMed Web of Science ®Google Scholar
• Pham T, van der Heijde D, Lassere M, et al. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol 2003;30:1648-54
   PubMed Web of Science ®Google Scholar
• Silverman DG, O’Connor TZ, Brull SJ. Integrated assessment of pain scores and rescue morphine use during studies of analgesic efficacy. Anesth Analg 1993;77:168-70
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clinics Geriatr Med 2010;26:355-69
   PubMed Web of Science ®Google Scholar
• Reginster JY, Distel M, Bluhmki E. A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br J Rheumatol 1996;35(Suppl 1):17-21
   PubMedGoogle Scholar
• Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996;35(Suppl 1):39-43
   PubMedGoogle Scholar
• Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2015; doi:10.1136/annrheumdis-2014-206792
   Web of Science ®Google Scholar
• Provenza JR, Shinjo SK, Silva JM, et al. Combined glucosamine and chondroitin sulfate, once or three times daily, provides clinically relevant analgesia in knee osteoarthritis. Clin Rheumatol 2014;34:1455-62
   PubMed Web of Science ®Google Scholar
• Dahlberg LE, Holme I, Hoye K, Ringertz B. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Scand J Rheumatol 2009;38:133-43
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Tannenbaum H, Patel NP, et al. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. BMC Musculoskel Disord 2008;9:32
   PubMed Web of Science ®Google Scholar
• Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch Fam Med 2000;9:1124-34
   PubMedGoogle Scholar
• Yocum D, Fleischmann R, Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med 2000;160:2947-54
   PubMed Web of Science ®Google Scholar
• Churchill L, Graham AG, Shih CK, et al. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology 1996;4:125-35
   Google Scholar
• Bruyère O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014;44:253-63
   PubMed Web of Science ®Google Scholar